Lynch syndrome is an inherited predisposition to several cancers, especially colorectal and endometrial cancer. It is not a cancer diagnosis, and carrying a causative variant does not mean cancer is inevitable. Understanding the result can support a more appropriate prevention and family assessment plan. [1] [2]
In this guide: Which genes are involved? · Tumor testing and inherited testing ask different questions · What does my genetic result mean? · What does this mean for relatives? · How is cancer risk managed? · For students and researchers: read risk estimates carefully · Your next-step checklist
Which genes are involved?
The central mismatch repair genes are MLH1, MSH2, MSH6 and PMS2. Certain deletions involving EPCAM can silence neighboring MSH2. These mechanisms can compromise the correction of DNA-copying errors. Risk patterns vary by gene and clinical context, so one overall “Lynch risk” percentage is an inadequate personal prediction. [2]
Colorectal and endometrial cancers are prominent, but other associated cancers can occur. The relevant family history includes cancer type and age at diagnosis on both sides of the family. A short or incomplete family history should be recorded as incomplete, not treated as proof that inherited susceptibility is absent. [1]
Tumor testing and inherited testing ask different questions
Tumor tests can examine mismatch repair protein staining or microsatellite instability. Abnormal findings may suggest the need for inherited-risk assessment, but they do not automatically prove Lynch syndrome. Further testing is needed to distinguish inherited findings from changes acquired in the tumor. [3]
For example, loss of MLH1 and PMS2 staining can result from tumor MLH1 promoter methylation rather than an inherited MLH1 variant. The appropriate additional investigations depend on tumor type and clinical context. Do not translate “mismatch repair deficient” directly into “my children inherited this.” [4]
Read tumor versus germline testing and the companion mismatch repair genes guide for more detail. Keep copies of both the pathology report and any germline genetic report; they describe different evidence.
What does my genetic result mean?
- Pathogenic or likely pathogenic finding: a clinically interpreted causative result can establish an inherited explanation and guide family testing.
- True negative for a known family variant: the specific familial finding was not detected. The clinician still considers other personal and family risk factors.
- Uninformative negative: no explanatory change was identified, but no known familial variant was available to rule out. This is not equivalent to proving there is no inherited susceptibility.
- Variant of uncertain significance: evidence is insufficient to decide its clinical meaning. It generally should not direct major risk-reducing decisions as though it were a confirmed cause.
The National Cancer Institute distinguishes these result types and explains why negative and uncertain findings require context. Ask who will reassess the finding if evidence changes. [5]
What does this mean for relatives?
Lynch syndrome usually follows autosomal dominant inheritance. A person with a causative variant has a 50% chance of transmitting it in each pregnancy; this is not a 50% estimate of that child’s cancer risk. When possible, genetic investigation starts with an affected relative, and a confirmed family variant can guide targeted testing of other relatives. [6] [3]
Our cascade testing guide explains why relatives should receive the precise laboratory finding rather than a verbal description. Ask the genetics team about a family letter, consent and which relatives should be approached. Avoid making assumptions about a relative’s result from their health history alone.
How is cancer risk managed?
Management commonly includes earlier and more frequent colonoscopy than population screening, with additional discussions based on the gene, age, organs present, family history and previous cancer. Gynecologic risk-reduction decisions, aspirin and other strategies require a professional discussion of benefits, limitations and harms. There is no single screening schedule that this article can safely assign to every reader. [7] [6]
A surveillance plan is a continuing process: record the responsible clinician, the next review date and what symptoms should prompt contact between scheduled visits. Do not start aspirin or arrange preventive surgery solely because an internet article mentions them.
For students and researchers: read risk estimates carefully
Before using a number from a Lynch syndrome paper, record the gene, cancer type, age range, recruitment method and whether participants had prior cancer or surveillance. Then ask whether the estimate describes cumulative risk to a stated age, risk over a follow-up interval or a relative comparison. Our penetrance guide and risk explainer provide the background vocabulary.
Reading exercise: rewrite a headline as “In this study population, carriers of this gene had this outcome over this time, with these uncertainties.” If the paper does not supply one element, mark it unknown. That sentence is more informative than importing a single percentage into a family conversation.
Your next-step checklist
- Collect pathology, tumor-testing and germline reports separately.
- Record the exact gene, variant, classification and report date.
- Write down cancer types and ages in relatives, including uncertainty.
- Ask whether the diagnosis is established or whether testing remains incomplete.
- Request a written surveillance and family communication plan.
Use the variant assistant to organize non-identifying evidence questions, the care finder for professional directories, and the research tools to locate original literature. Browse other inherited conditions in the disease finder.
Does a tumor result mean my relatives should immediately be tested?
It can justify genetic evaluation, but the inherited finding first needs clarification. Ask which germline result, if any, provides a valid target for relatives. [3]
Educational information. Individual screening, treatment and reproductive decisions require qualified professional advice.